文献速递胸部肿瘤头颈与中枢神经肿瘤骨软组织肉瘤与黑色素瘤

GPNMB通过重塑病理性内皮-免疫互作驱动脑转移

GPNMB Drives Brain Metastasis by Sculpting a Pathologic Endothelial-Immune Interactome.
PubMed 文献 · Cancer Discov · 2026-01-01

该研究利用循环肿瘤细胞(CTC)与脑转移灶的空间多组学分析结合实验与临床验证,发现CTC分泌的GPNMB通过CBX3-GPNMB-EGFR-FTO-TJP1轴破坏血脑屏障并促进脑定植。GPNMB诱导的屏障重塑经CXCL12-CXCR4轴促进免疫浸润并诱导T细胞耗竭。临床上CBX3+GPNMB+ CTCs和血浆CXCL12与肺癌和黑色素瘤脑转移进展显著相关,GPNMB/PD1双阻断在小鼠中增强抗脑转移疗效。

要点

  • CTC分泌GPNMB通过靶向内皮EGFR降解破坏血脑屏障。
  • GPNMB诱导的屏障重塑经CXCL12-CXCR4轴促进免疫浸润和T细胞耗竭。
  • GPNMB/PD1双阻断增强小鼠抗脑转移疗效。

核心结论

  • GPNMB是CTC分泌的驱动血脑屏障破坏和脑定植的关键分子,靶向GPNMB联合PD1具有抗脑转移潜力。

研究设计与样本

  • 研究采用空间分辨多组学分析CTC和脑转移灶,并结合实验与临床分析。

主要发现

  • CBX3上调诱导GPNMB表达,GPNMB结合内皮EGFR触发CBL介导的泛素化和降解。
  • EGFR信号减弱抑制FTO并通过YTHDF2依赖的TJP1 m6A甲基化破坏内皮连接。
  • GPNMB诱导的血脑屏障重塑通过CXCL12-CXCR4轴促进免疫浸润并诱导时间依赖性T细胞耗竭。
  • 临床上升高的CBX3+GPNMB+ CTCs和血浆CXCL12与肺癌和黑色素瘤脑转移进展显著相关。
  • 小鼠中GPNMB和PD1双阻断增强抗脑转移疗效。

关键数值与推荐

  • CBX3+GPNMB+ CTCs和血浆CXCL12可作为脑转移管理的非侵入性生物标志物。

临床怎么用

  • 检测CBX3+GPNMB+ CTCs和血浆CXCL12可能有助于脑转移进展监测。
  • GPNMB/PD1双阻断为脑转移精准免疫治疗提供新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Brain metastasis remains a devastating disease with dismal prognosis. How circulating tumor cells (CTC) penetrate the blood-brain barrier (BBB) and reprogram the brain microenvironment remains unclear. Using spatially resolved multi-omics profiling of CTCs and brain metastases, integrated with experimental and clinical analyses, we identified glycoprotein nonmetastatic melanoma protein B (GPNMB) as a CTC-secreted driver of vascular disruption and brain colonization. CBX3 upregulation induced GPNMB expression, which bound endothelial EGFR, triggering CBL-mediated ubiquitination and degradation. Attenuated EGFR signaling suppressed FTO and disrupted endothelial junctions via YTHDF2-dependent TJP1 m6A methylation. Remarkably, GPNMB-induced BBB remodeling promoted immune infiltration via the CXCL12-CXCR4 axis and induced time-course-dependent T-cell exhaustion within the brain microenvironment. Clinically, elevated CBX3+GPNMB+ CTCs and plasma CXCL12 were significantly associated with brain metastasis progression in lung cancer and melanoma. Therapeutically, dual blockade of GPNMB and PD1 enhanced anti-brain metastasis efficacy in mice, unveiling GPNMB as a promising target for precision immunotherapy. SIGNIFICANCE: GPNMB is a CTC-secreted driver of BBB disruption and brain colonization via the CBX3-GPNMB-EGFR-FTO-TJP1 axis. GPNMB-induced BBB remodeling promotes CXCL12-CXCR4-mediated immune infiltration and enhances T-cell exhaustion, sensitizing brain metastasis tumors to GPNMB/PD1 dual blockade. CBX3+GPNMB+ CTCs and plasma CXCL12 may serve as noninvasive biomarkers for brain metastasis management.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Liu X, Tan J, Wu C, et al. GPNMB Drives Brain Metastasis by Sculpting a Pathologic Endothelial-Immune Interactome. Cancer Discov. 2026. PMID: 41973996. doi:10.1158/2159-8290.CD-25-1663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。